DDInter1576 DDInter1435
Regorafenib is an orally-administered inhibitor of multiple kinases. It is used for the treatment of metastatic colorectal cancer, advanced gastrointestinal stromal tumours, and hepatocellular carcinoma. FDA approved on September 27, 2012. Approved use of Regorafenib was expanded to treat Hepatocellular Carcinoma in April 2017.
Pexidartinib is a selective tyrosine kinase inhibitor that works by inhibiting the colony-stimulating factor (CSF1)/CSF1 receptor pathway. Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor. Tenosynovial giant cell tumor is a rare form of non-malignant tumor that causes the synovium and tendon sheaths to thicken and overgrow, leading to damage in surrounding joint tissue.[A182240,L7901] Debilitating symptoms often follow with tenosynovial giant cell tumors, along with a risk of significant functional limitations and a reduced quality of life in patients. While surgical resection is a current standard of care for tenosynovial giant cell tumor, there are tumor types where surgeries are deemed clinically ineffective with a high risk of lifetime recurrence. Pexidartinib works by blocking the immune responses that are activated in tenosynovial giant cell tumors. In clinical trials, pexidartinib was shown to promote improvements in patient symptoms and functional outcomes in TGCT. Pexidartinib is available in oral formulations and it is commonly marketed as Turalio.
Regorafenib {u} (Compound) resembles {v} (Compound) Sorafenib
Regorafenib {u} (Compound) binds {v} (Gene) CYP2C9
Regorafenib {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 2C9 Inhibitors
Regorafenib {u} (Compound) causes {v} (Side Effect) Myocardial infarction
Regorafenib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Dapagliflozin
Regorafenib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Dolutegravir
Regorafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Irinotecan
Regorafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Abametapir
Regorafenib {u} may lead to a major life threatening interaction when taken with {v} Fondaparinux
Regorafenib {u} may lead to a major life threatening interaction when taken with {v} Venetoclax
Regorafenib (Compound) resembles Sorafenib (Compound)
Regorafenib (Compound) binds CYP2C9 (Gene)
Regorafenib (Compound) is included by Cytochrome P450 2C9 Inhibitors (Pharmacologic Class)
Regorafenib (Compound) causes Myocardial infarction (Side Effect)
Regorafenib may cause a minor interaction that can limit clinical effects when taken with Dapagliflozin
Regorafenib may cause a minor interaction that can limit clinical effects when taken with Dolutegravir
Regorafenib may cause a moderate interaction that could exacerbate diseases when taken with Irinotecan
Regorafenib may cause a moderate interaction that could exacerbate diseases when taken with Abametapir
Regorafenib may lead to a major life threatening interaction when taken with Fondaparinux
Regorafenib may lead to a major life threatening interaction when taken with Venetoclax